Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 10/20 | 0.53 |
| ▸ | ACHE | P22303 | 9/20 | 0.53 |
| ▸ | MEN1 | O00255 | 8/20 | 0.53 |
| ▸ | RAB9A | P51151 | 8/20 | 0.53 |
| ▸ | NPC1 | O15118 | 6/20 | 0.53 |
| ▸ | POLB | P06746 | 5/20 | 0.53 |
| ▸ | HTT | P42858 | 4/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.53 |
| ▸ | MAPT | P10636 | 4/20 | 0.53 |
| ▸ | LMNA | P02545 | 3/20 | 0.53 |
| ▸ | BLM | P54132 | 3/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.53 |
| ▸ | BCHE | P06276 | 3/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.53 |
| ▸ | THRB | P10828 | 2/20 | 0.53 |
| ▸ | RECQL | P46063 | 2/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.53 |
| ▸ | PPARG | P37231 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18349199 | 0.92 | KMT2A (0.55) | KMT2AACHEMEN1RAB9ANPC1 | |
| SCHEMBL18349255 | 0.91 | KMT2A (0.54) | KMT2AACHEMEN1RAB9ANPC1 | |
| SCHEMBL18349215 | 0.87 | KMT2A (0.54) | KMT2AACHEMEN1RAB9ANPC1 | |
| SCHEMBL19860016 | 0.78 | KMT2A (0.69) | KMT2AACHEMEN1RAB9ANPC1 | |
| SCHEMBL18349232 | 0.78 | RAB9A (0.41) | KMT2AACHEMEN1RAB9ANPC1 | |
| SCHEMBL18349205 | 0.75 | KMT2A (0.70) | KMT2AACHEMEN1RAB9ANPC1 | |
| SCHEMBL20285878 | 0.73 | MEN1 (0.42) | KMT2AACHEMEN1RAB9ANPC1 | |
| SCHEMBL18349256 | 0.73 | KMT2A (0.70) | KMT2AACHEMEN1RAB9ANPC1 | |
| SCHEMBL5675231 | 0.71 | ACHE (0.97) | KMT2AACHEMEN1RAB9ANPC1 | |
| SCHEMBL5675236 | 0.71 | ACHE (0.97) | KMT2AACHEMEN1RAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180170953-A1 | PROTOTYPE SYSTEMS OF THERANOSTIC BIOMARKERS FOR IN VIVO MOLECULAR MANAGEMENT OF CANCER | EPOS-IASIS RESEARCH AND DEVELOPMENT, LTD (CY) | 2018-06-21 | — | — | US | disclosed |
| US-9890187-B2 | Prototype systems of theranostic biomarkers for in vivo molecular management of cancer | EPOS-IASIS RESEARCH AND DEVELOPMENT, LTD. (CY) | 2018-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180170953-A1 | PROTOTYPE SYSTEMS OF THERANOSTIC BIOMARKERS FOR IN VIVO MOLECULAR MANAGEMENT OF CANCER | TP53, MKI67, FLT3 | KMT2A 2199/4885ACHE 4714/4885MEN1 1887/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.